Inhibrx Biosciences Inc (INBX) Stock Price, Quote & News

Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma,...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 795 4220

Website: inhibrx.com

Address:

11025 North Torrey Pines Road, Suite 140, La Jolla, United States

JarvisFlow May. 15 at 2:02 PM

JMP Securities updates rating for Inhibrx Biosciences ( $INBX ) to Market Perform.

0 · Reply

Armonica423 May. 10 at 7:11 PM

$INBX Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

justiceforb_85 May. 2 at 5:20 AM

$INBX thoughts on the probability of ozekibart being effective in chondrosarcoma?

1 · Reply

TrendTrade8696 Apr. 7 at 3:53 PM

$INBX INBX is focusing solely on the development and commercialization of its promising oncology and rare disease therapeutic candidates. The company's clinical pipeline now includes ozekibart INBRX-109, a tetravalent death receptor 5 (DR5) agonist, and INBRX-106, a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40. Close to $12/sh in cash and LOTS of insider buying over last 10 months

0 · Reply

TrendTrade8696 Apr. 7 at 3:32 PM

$INBX Looking at balance sheet INBX has almost $12/sh in cash.... hmmmm

0 · Reply

Thestocktraderhubzee Apr. 2 at 10:10 AM

WATCHLIST APR 02 2025. $EWTX Edgewise Therapeutics Announced Topline Data Of EDG-7500 From The Phase 2 CIRRUS-HCM Four-week Trial In Participants With Obstructive Or Nonobstructive Hypertrophic Cardiomyopathy $GLSI Greenwich Lifesciences Announces Immune Response Data From FLAMINGO-01 Phase 3 Clinical Trial $AULT Autolus Therapeutics shares are trading lower after Truist Securities cut its price target on the stock from $11 to $10. $JNJ Johnson & Johnson Announces Expected Closing Date For Intra-Cellular Acquisition; To Complete Intra-Cellular Acquisition Around April 2, 2025 $INBX Inhibrx Biosciences Announces Departure Of Dr. Brendan Eckelman, Co-founder And Chief Scientific Officer And Appoints Dr. Carlos Bais And David Matly to CSO and President, Respectively

0 · Reply

NVDAMillionaire Mar. 21 at 9:48 AM

$INBX Digging INBX's oncology pipeline. Regeneron partnership looks promising. Phase 2 data for ozekibart in mid-2025 could be a game changer. Watching closely. polished article: https://beyondspx.com/article/inhibrx-biosciences-inbx-navigating-the-oncology-and-rare-disease-landscape-with-a-robust-pipeline-and-strategic-transactions

0 · Reply

JarvisFlow Mar. 18 at 2:35 PM

Citizens Capital Markets has updated their rating for Inhibrx Biosciences ( $INBX ) to Market Perform.

0 · Reply

DonCorleone77 Mar. 17 at 8:14 PM

$INBX Inhibrx reports Q4 EPS ($3.09) vs. ($6.93) last year Reports Q4 revenue $100,000 vs. $1.63M last year.

0 · Reply

UncleStock Mar. 7 at 9:02 PM

$SQNS $SNAL $GOLF $INBX suggested for Greenblatt - value screen: https://zpr.io/UTuPZph7JaaR

0 · Reply

Inhibrx Reports First Quarter 2025 Financial Results

Apr 1, 2025, 4:05 PM EDT - 3 months ago

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Mar 17, 2025, 4:05 PM EDT - 3 months ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Jan 21, 2025, 5:01 PM EST - 5 months ago

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Jan 13, 2025, 4:15 PM EST - 5 months ago

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Nov 14, 2024, 4:24 PM EST - 8 months ago

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 11:45 AM EST - 8 months ago

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Nov 4, 2024, 4:00 PM EST - 8 months ago

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Aug 27, 2024, 7:10 AM EDT - 10 months ago

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying

HNRG TCBI

Aug 13, 2024, 6:54 PM EDT - 11 months ago

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Jun 7, 2024, 2:42 PM EDT - 1 year ago

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Jun 5, 2024, 7:46 AM EDT - 1 year ago

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

A EXAS TDOC

May 24, 2024, 4:00 PM EDT - 1 year ago

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

May 10, 2024, 6:36 PM EDT - 1 year ago

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

May 9, 2024, 3:36 PM EDT - 1 year ago

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SNY

May 8, 2024, 4:37 PM EDT - 1 year ago

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Feb 28, 2024, 9:15 AM EST - 1 year ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Jan 23, 2024, 11:45 AM EST - 1 year ago

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

SNY

Jan 23, 2024, 5:39 AM EST - 1 year ago

Sanofi to Buy Rare-Disease Assets From Inhibrx

SNY

Jan 23, 2024, 1:32 AM EST - 1 year ago

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

SNY

Jan 23, 2024, 1:30 AM EST - 1 year ago

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

SNY

Jan 23, 2024, 1:00 AM EST - 1 year ago

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

SNY

Nov 9, 2023, 4:00 PM EST - 1 year ago

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:15 AM EDT - 1 year ago

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Oct 18, 2023, 4:00 PM EDT - 1 year ago

Inhibrx Announces Participation in Upcoming Scientific Conferences

Sep 19, 2023, 4:00 PM EDT - 1 year ago

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Sep 1, 2023, 4:26 PM EDT - 1 year ago

Andreas Halvorsen's Firm Ups Inhibrx Stake

Aug 29, 2023, 9:00 AM EDT - 1 year ago

Inhibrx Announces $200 Million Private Placement Financing

Aug 17, 2023, 4:41 PM EDT - 2 years ago

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

Aug 7, 2023, 4:00 PM EDT - 2 years ago

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

May 30, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 8, 2023, 4:05 PM EDT - 2 years ago

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Apr 26, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Apr 13, 2023, 11:12 AM EDT - 2 years ago

Inhibrx: Undercovered Company With Good Potential

Mar 6, 2023, 4:05 PM EST - 2 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Jan 4, 2023, 9:00 AM EST - 2 years ago

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

Nov 18, 2022, 4:05 PM EST - 2 years ago

Inhibrx Announces Participation in Upcoming Investor Conference

Nov 16, 2022, 9:00 AM EST - 2 years ago

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

Nov 7, 2022, 4:05 PM EST - 2 years ago

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Oct 4, 2022, 8:00 AM EDT - 2 years ago

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Oct 3, 2022, 4:30 PM EDT - 2 years ago

Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

Aug 15, 2022, 4:05 PM EDT - 3 years ago

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

Aug 8, 2022, 5:19 PM EDT - 3 years ago

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Jun 30, 2022, 9:00 AM EDT - 3 years ago

Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance

Jun 10, 2022, 1:29 PM EDT - 3 years ago

Inhibrx: Potential To Move To Registration Study With INBRX-101

May 19, 2022, 4:05 PM EDT - 3 years ago

Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting

May 16, 2022, 12:42 PM EDT - 3 years ago

Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder

May 16, 2022, 9:00 AM EDT - 3 years ago

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

JarvisFlow May. 15 at 2:02 PM

JMP Securities updates rating for Inhibrx Biosciences ( $INBX ) to Market Perform.

0 · Reply

Armonica423 May. 10 at 7:11 PM

$INBX Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

justiceforb_85 May. 2 at 5:20 AM

$INBX thoughts on the probability of ozekibart being effective in chondrosarcoma?

1 · Reply

TrendTrade8696 Apr. 7 at 3:53 PM

0 · Reply

TrendTrade8696 Apr. 7 at 3:32 PM

$INBX Looking at balance sheet INBX has almost $12/sh in cash.... hmmmm

0 · Reply

Thestocktraderhubzee Apr. 2 at 10:10 AM

0 · Reply

NVDAMillionaire Mar. 21 at 9:48 AM

0 · Reply

JarvisFlow Mar. 18 at 2:35 PM

Citizens Capital Markets has updated their rating for Inhibrx Biosciences ( $INBX ) to Market Perform.

0 · Reply

DonCorleone77 Mar. 17 at 8:14 PM

$INBX Inhibrx reports Q4 EPS ($3.09) vs. ($6.93) last year Reports Q4 revenue $100,000 vs. $1.63M last year.

0 · Reply

UncleStock Mar. 7 at 9:02 PM

$SQNS $SNAL $GOLF $INBX suggested for Greenblatt - value screen: https://zpr.io/UTuPZph7JaaR

0 · Reply

UncleStock Feb. 20 at 8:39 PM

$INBX $AISP $ROIV $IMKTA suggested for Greenblatt - value screen: https://zpr.io/UTuPZph7JaaR

0 · Reply

UncleStock Feb. 13 at 6:21 PM

$IH $ROIV $RSSS $INBX suggested for Greenblatt - value screen: https://zpr.io/UTuPZph7JaaR

0 · Reply

UncleStock Feb. 10 at 3:05 AM

$SNAL $INBX $CANG $ROIV suggested for Greenblatt - value screen: https://zpr.io/UTuPZph7JaaR

0 · Reply

Thestocktraderhubzee Jan. 22 at 9:00 AM

WATCHLIST JAN 22 2025 $AVBP ArriVent BioPharma Entered Exclusive License With Lepu Biopharma For MRG007, An Antibody Drug Conjugate For Treatment Of Gastrointestinal Cancers $INBX Inhibrx Reports Preliminary Efficacy And Safety Data From Phase 1 Trial Of Ozekibart (INBRX-109) For Treatment Of Colorectal Cancer; Initiates New Expansion Cohort To Validate Findings $CRSP Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases $NTRA Reported Earlier, Natera To Reveal New Insights On Signatera's Clinical Utility And Innovations In Tissue-Free MRD At ASCO GI 2025 $EXAS Exact Sciences Says Oncodetect Test Achieved Primary Endpoint In Second Clinical Validation Study, Extending Prognostic Value Into Stages II And IV Colon Cancer And Rectal Cancer

0 · Reply

UncleStock Jan. 17 at 7:13 AM

$ROIV $QSG $SNAL $INBX suggested for Greenblatt - value screen: https://zpr.io/UTuPZph7JaaR

0 · Reply

stockRDA Dec. 31 at 5:46 PM

$INBX all I can say is lots of buying from CEO and Director. Also gifting tons of shares in trust to children. Looking for a pullback before I open a position.

1 · Reply

NVDAMillionaire Nov. 26 at 3:15 AM

$INBX Inhibrx Biosciences (NASDAQ:INBX): A Resilient Biopharmaceutical Innovator Navigating the Complexities of the Oncology Landscape https://beyondspx.com/article/inhibrx-biosciences-nasdaq-inbx-a-resilient-biopharmaceutical-innovator-navigating-the-complexities-of-the-oncology-landscape

0 · Reply

Bullish_Swagger Nov. 10 at 8:45 PM

Here is where big money is making their bets... $TTSH $INBX $BCOV

0 · Reply

taotrader Nov. 8 at 2:00 PM

$INBX why is this down -20% premarket? I can’t find any news anywhere.

1 · Reply

UncleStock Oct. 19 at 7:42 PM

$INBX $ICG $IH $ROIV suggested for Greenblatt - value screen: https://zpr.io/UTuPZph7JaaR

0 · Reply

UncleStock Oct. 16 at 6:31 AM

$INBX $ICG $IH $CANG suggested for Greenblatt - value screen: https://zpr.io/UTuPZph7JaaR

0 · Reply

Market Cap	214.10M
Revenue (ttm)	200,000.00
Net Income (ttm)	1.69B
EPS (ttm)	N/A
PE Ratio	0.13
Forward PE	N/A
Profit Margin	843,784.96%
Debt to Equity Ratio	0.00

Volume	393,100
Avg Vol	92,372
Day's Range	N/A - N/A
Shares Out	14.48M
Stochastic %K	15%
Beta	N/A
Analysts	Hold
Price Target	$12.00